Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation

被引：17

作者：

Tsirigotis, P. ^{[1
]}

Danylesko, I. ^{[2
]}

Gkirkas, K. ^{[1
]}

Shem-Tov, N. ^{[2
]}

Yerushalmi, R. ^{[2
]}

Stamouli, M. ^{[1
]}

Avigdor, A. ^{[2
]}

Spyridonidis, A. ^{[3
]}

Gauthier, J. ^{[4
]}

Goldstein, G. ^{[2
]}

Apostolidis, J. ^{[5
,6
]}

Mohty, M. ^{[7
]}

Shimoni, A. ^{[2
]}

Nagler, A. ^{[2
]}

机构：

[1] Univ Athens, ATTIKO Univ Hosp, Dept Internal Med 2, Rimini 1, Athens 2462, Greece

[2] Chaim Sheba Med Ctr, Div Hematol, Tel Aviv, Israel

[3] Univ Patras, Bone Marrow Transplantat Unit, Patras, Greece

[4] Univ Lille, Bone Marrow Transplantat Unit, Lille, France

[5] Evaggelismos Gen Hosp, Bone Marrow Transplantat & Hematol, Athens, Greece

[6] Evaggelismos Gen Hosp, Lymphoma Dept, Athens, Greece

[7] Hosp St Antoine, Dept Hematol, Paris, France

来源：

BONE MARROW TRANSPLANTATION | 2016年 / 51卷 / 10期

关键词：

ANDERSON-CANCER-CENTER; MARROW TRANSPLANTATION; EUROPEAN GROUP; WORKING PARTY; EXPERIENCE; RELAPSE; BLOOD;

D O I：

10.1038/bmt.2016.129

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

In our study, we evaluated the safety and efficacy of Brentuximab vedotin (BV) with or without the addition of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation (allo-SCT) in 16 patients with advanced Hodgkin lymphoma (HL). Thirteen patients with relapsed HL after allo-SCT received BV as treatment for active disease. Three patients without progression of HL after allo-SCT received BV as consolidation. Twelve patients had been previously exposed to BV for treatment of relapse after autologousSCT. Ten out of 16 patients received BV in combination with DLI. Among the 13 patients treated for active disease, CR and PR was observed in 7 and 2 patients, respectively. With a median follow-up of 13 months, 13 out of 16 patients are alive, while 3 died because of disease progression. The median PFS was 6 months. DLI-associated GVHD occurred in seven patients. Five patients with GVHD required immunosuppression, and in all cases, GVHD resolved after a short course of low dose steroids, implying that an antiGVHD modulating effect could be induced by the concurrent administration of BV. No serious adverse event was observed in any of the patients.

引用

页码：1313 / 1317

页数：5

共 14 条

[1] Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma:: Results of a Spanish prospective cooperative protocol [J].

Alvarez, I ;

Sureda, A ;

Caballero, MD ;

Urbano-Ispizzua, A ;

Ribera, JM ;

Canales, M ;

García-Conde, J ;

Sanz, G ;

Arranz, R ;

Bernal, MT ;

de la Serna, J ;

Díez, JL ;

Moraleda, JM ;

Rubió-Félix, D ;

Xicoy, B ;

Martínez, C ;

Mateos, MV ;

Sierra, J .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) :172-183

[2] Fludarabine-meiphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated MD Anderson Cancer Center experience [J].

Anderlini, Paolo ;

Saliba, Rima ;

Acholonu, Sandra ;

Giralt, Sergio A. ;

Andersson, Borje ;

Ueno, Naoto T. ;

Hosing, Chitra ;

Khouri, Issa F. ;

Couriel, Daniel ;

de Lima, Marcos ;

Qazilbash, Muzaffar H. ;

Pro, Barbara ;

Romaguera, Jorge ;

Fayad, Luis ;

Hagemeister, Frederick ;

Younes, Anas ;

Munsell, Mark F. ;

Champlin, Richard E. .

HAEMATOLOGICA, 2008, 93 (02) :257-264

[3] Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the MD Anderson Cancer Center [J].

Anderlini, Paolo ;

Saliba, Rima ;

Acholonu, Sandra ;

Okoroji, Grace-Julia ;

Ledesma, Celina ;

Andersson, Borje S. ;

Jones, Roy ;

Popat, Uday R. ;

Hosing, Chitra M. ;

Nieto, Yago ;

Qazilbash, Muzaff Ar H. ;

Ueno, Naoto T. ;

Giralt, Sergio A. ;

de Lima, Marcos J. ;

Champlin, Richard E. .

LEUKEMIA & LYMPHOMA, 2012, 53 (06) :1239-1241

[4] Brentuximab Vedotin in Patients With Hodgkin Lymphoma and a Failed Allogeneic Stem Cell Transplantation: Results From a Named Patient Program at Four Italian Centers [J].

Carlo-Stella, Carmelo ;

Ricci, Francesca ;

Dalto, Serena ;

Mazza, Rita ;

Malagola, Michele ;

Patriarca, Francesca ;

Viviani, Simonetta ;

Russo, Domenico ;

Giordano, Laura ;

Castagna, Luca ;

Corradini, Paolo ;

Santoro, Armando .

ONCOLOGIST, 2015, 20 (03) :323-328

[5] Expression of CD30 in patients with acute graft-versus-host disease [J].

Chen, Yi-Bin ;

McDonough, Sean ;

Hasserjian, Robert ;

Chen, Heidi ;

Coughlin, Erin ;

Illiano, Christina ;

Park, In Sun ;

Jagasia, Madan ;

Spitzer, Thomas R. ;

Cutler, Corey S. ;

Soiffer, Robert J. ;

Ritz, Jerome .

BLOOD, 2012, 120 (03) :691-696

[6] Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification [J].

Cheson, Bruce D. ;

Fisher, Richard I. ;

Barrington, Sally F. ;

Cavalli, Franco ;

Schwartz, Lawrence H. ;

Zucca, Emanuele ;

Lister, T. Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3059-+

[7] Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation [J].

Gopal, Ajay K. ;

Ramchandren, Radhakrishnan ;

O'Connor, Owen A. ;

Berryman, Robert B. ;

Advani, Ranjana H. ;

Chen, Robert ;

Smith, Scott E. ;

Cooper, Maureen ;

Rothe, Achim ;

Matous, Jeffrey V. ;

Grove, Laurie E. ;

Zain, Jasmine .

BLOOD, 2012, 120 (03) :560-568

[8] Outcomes of Hodgkin's Lymphoma Patients with Relapse or Progression following Autologous Hematopoietic Cell Transplantation [J].

Kaloyannidis, Panayotis ;

Voutiadou, Georgia ;

Baltadakis, Loannis ;

Tsirigotis, Panagiotis ;

Spyridonidis, Alexandros ;

Repousis, Panagiotis ;

Balta, Artemisia ;

Tsimberis, Simeon ;

Karakasis, Dimitrios ;

Sakellari, Ioanna ;

Dervenoulas, Ioannis ;

Harhalakis, Nicholas ;

Anagnostopoulos, Achilles .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (03) :451-457

[9] Donor Lymphocyte Infusions Modulate Relapse Risk in Mixed Chimeras and Induce Durable Salvage in Relapsed Patients After T-Cell-Depleted Allogeneic Transplantation for Hodgkin's Lymphoma [J].

Peggs, Karl S. ;

Kayani, Irfan ;

Edwards, Noha ;

Kottaridis, Panagiotis ;

Goldstone, Anthony H. ;

Linch, David C. ;

Hough, Rachael ;

Morris, Emma C. ;

Fielding, Adele ;

Chakraverty, Ronjon ;

Thomson, Kirsty J. ;

Mackinnon, Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) :971-978

[10] Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome [J].

Robinson, Stephen P. ;

Sureda, Anna ;

Canals, Carmen ;

Russell, Nigel ;

Caballero, Dolores ;

Bacigalupos, Andrea ;

Iriondo, Arturo ;

Cook, Gordon ;

Pettitt, Andrew ;

Socie, Gerard ;

Bonifazi, Francesca ;

Bosi, Alberto ;

Michallet, Mauricette ;

Liakopoulou, Effie ;

Maertens, Johan ;

Passweg, Jakob ;

Clarke, Fiona ;

Martin, Rodrigo ;

Schmitz, Norbert .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (02) :230-238

← 1 2 →